Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Fennec Pharmaceuticals (NASDAQ: FENC), a commercial stage specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025. The results will be released before U.S. markets open, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
The company will host a live webcast accessible through their website, with a replay available for thirty days following the event. Participants are advised to connect at least 15 minutes early to allow for any necessary software downloads.
Fennec Pharmaceuticals (NASDAQ: FENC), azienda farmaceutica specializzata in fase commerciale, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per giovedì 14 agosto 2025. I risultati saranno diffusi prima dell'apertura dei mercati statunitensi e saranno seguiti da una conference call e un webcast con la direzione alle 8:30 (Eastern Time).
L'azienda trasmetterà il webcast in diretta sul proprio sito web e la registrazione sarà disponibile per trenta giorni dopo l'evento. Si raccomanda ai partecipanti di collegarsi almeno 15 minuti prima per permettere l'eventuale download del software necessario.
Fennec Pharmaceuticals (NASDAQ: FENC), compañía farmacéutica especializada en fase comercial, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 14 de agosto de 2025. Los resultados se publicarán antes de la apertura de los mercados estadounidenses y a continuación habrá una conferencia telefónica y webcast con la dirección a las 8:30 a.m., hora del Este.
La empresa ofrecerá un webcast en directo accesible desde su sitio web, y la repetición estará disponible durante treinta días tras el evento. Se recomienda a los participantes conectarse al menos 15 minutos antes para permitir la descarga de cualquier software necesario.
펜넥 파마슈티컬스(NASDAQ: FENC)는 상업 단계의 전문 제약사로, 2025년 2분기 재무실적 발표를 2025년 8월 14일 목요일로 예정했습니다. 실적은 미국 증시 개장 전 공개되며, 이어 경영진의 컨퍼런스 콜과 웹캐스트가 동부 시간 오전 8시 30분에 진행됩니다.
회사는 자사 웹사이트를 통해 라이브 웹캐스트를 제공하며, 이벤트 후 30일간 재생을 이용할 수 있습니다. 참가자는 필요한 소프트웨어 다운로드를 위해 최소 15분 전에 접속할 것을 권장합니다.
Fennec Pharmaceuticals (NASDAQ: FENC), une société pharmaceutique spécialisée en phase commerciale, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 14 août 2025. Les résultats seront diffusés avant l'ouverture des marchés américains, suivis d'une conférence téléphonique de la direction et d'un webcast à 8h30, heure de l'Est.
L'entreprise proposera un webcast en direct accessible depuis son site web, dont le replay sera disponible pendant trente jours après l'événement. Les participants sont invités à se connecter au moins 15 minutes à l'avance afin de permettre le téléchargement éventuel de logiciels.
Fennec Pharmaceuticals (NASDAQ: FENC), ein auf dem Markt etabliertes Spezialpharmaunternehmen, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 14. August 2025 terminiert. Die Ergebnisse werden vor Öffnung der US-Märkte veröffentlicht, gefolgt von einer Management-Konferenzschaltung und einem Webcast um 8:30 Uhr Eastern Time.
Das Unternehmen überträgt den Webcast live über seine Website; eine Wiederholung steht für dreißig Tage nach der Veranstaltung zur Verfügung. Teilnehmer sollten sich mindestens 15 Minuten früher einwählen, um eventuelle Software-Downloads durchzuführen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
Date: Thursday, August 14, 2025
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/de4jxxzj
Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b46f60abda54
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced hearing loss, or ototoxicity. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q2 2025 earnings?
What time is Fennec Pharmaceuticals' Q2 2025 earnings call?
How can investors access Fennec Pharmaceuticals' Q2 2025 earnings call?
Will there be a replay of Fennec Pharmaceuticals' Q2 2025 earnings call?
